Less than one in 10 individuals that would benefit from weight-loss injections such as Wegovy can access them, states the World Health Organization as it releases its initial recommendations on the therapies.
Considering in excess of 1,000,000,000 individuals worldwide now obese, it is advocating for increased and just availability to this class of drugs.
Based on projections, in excess of 2,000,000,000 will be living with obesity by 2030 unless action is taken.
"The latest guidelines recognises that obesity is a chronic disease that can be managed with comprehensive and continuous support," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are key hurdles to universal access to the treatments that can aid individuals in losing significant body mass, notes the organization.
GLP-1 Therapy Supply Crisis
Even under the current most favorable outlook, the supply of such drugs could only cover around 100 million people – under 10% of those who need them, according to the WHO.
The guideline calls on nations and manufacturers to increase availability, through strategies like licensing agreements.
A patent on semaglutide – the core component of a leading brand – is set to lapse in a number of nations in 2026.
The Way Obesity Jabs Function
These medications imitate a biological compound to reduce digestion speed, curb appetite and increase satiety so users reduce food intake.
Individuals commonly see weight reduction within a few weeks of starting on the regular doses.
Evidence indicates users may put most of the weight back on within a year of discontinuing the drug, because their usual hunger come back.
To be above a healthy weight elevates your likelihood for developing diseases, including type 2 diabetes, heart disease, stroke, and specific malignancies.
Obesity concerns people in countries worldwide and was linked to millions of deaths worldwide in 2024, as per the health agency.
